#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
As medical cannabis prescriptions in the UK reach 1.7 million annually, clinicians need current evidence on efficacy and safety profiles across common indications to make informed prescribing decisions for their patients. The approaching ACMD review will likely reshape regulatory frameworks and access pathways, directly affecting which patients can legally obtain cannabis-based treatments and under what clinical circumstances. Tracking prescription volumes and outcomes data helps clinicians understand real-world effectiveness patterns and identify which patient populations may benefit most from cannabis-based interventions versus conventional therapies.
Medical cannabis prescriptions in the United Kingdom reached 1.7 million in 2025, representing substantial growth in clinical utilization and suggesting increasing physician acceptance of cannabis-based medicines within the National Health Service framework. This expansion occurs as the Advisory Council on the Misuse of Drugs (ACMD) prepares to conduct a comprehensive review of medical cannabis policy, which will likely shape future prescribing guidelines and regulatory requirements. The reported alignment between supply and demand indicates a maturing market with improved access and distribution infrastructure for patients seeking cannabis-based treatments. The upcoming ACMD review will be critical in determining whether additional indications, formulations, or patient populations should be included in the medical cannabis framework, potentially affecting prescriber confidence and utilization patterns. For clinicians in the UK and other jurisdictions considering medical cannabis adoption, the scale of these prescriptions and the formal policy review signal growing clinical legitimacy, though evidence-based outcome measurement will be essential to justify continued expansion and secure long-term integration into standard care pathways.
“We’re seeing real-world utilization data now from the UK that gives us important context, but prescription volume alone doesn’t tell us about efficacy or safety outcomes, which is exactly what the ACMD review should be examining. Until we have systematic data on which patients benefit, which don’t, and what the actual harms are in practice, we’re still operating with incomplete clinical intelligence.”
💊 The substantial growth in UK medical cannabis prescriptions to 1.7 million in 2025 reflects increasing clinician familiarity and patient demand, yet this expansion occurs amid ongoing uncertainty about long-term efficacy, optimal dosing strategies, and comparative effectiveness against conventional therapies for most conditions. The apparent alignment between supply and demand suggests a maturing market, though prescribing patterns may reflect enthusiasm that outpaces robust outcome data rather than clearly established clinical superiority in most indications beyond well-studied conditions like treatment-resistant epilepsy. Clinicians should recognize that increased prescription volume does not inherently validate therapeutic benefit, and the forthcoming ACMD review will be critical in establishing evidence-based criteria for appropriate use. As medical cannabis becomes more embedded in routine practice, healthcare providers need to systematically collect and report outcomes data on their patient populations to contribute to the evidence base and ensure prescribing decisions are grounded in demonstrated benefit rather
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
